Department of Pathology, Tianjin Haihe Hospital, Tianjin Institute of Respiratory Diseases, Tianjin, 300350, China.
Department of Pathology, Tianjin Jinnan Hospital, Tianjin 300350, China.
Comb Chem High Throughput Screen. 2022;25(9):1565-1575. doi: 10.2174/1871520621666210713112630.
This study aims to explore the prognostic values of CT83 and CT83- related genes in lung adenocarcinoma (LUAD).
We downloaded the mRNA profiles of 513 LUAD patients (RNA sequencing data) and 246 NSCLC patients (Affymetrix Human Genome U133 Plus 2.0 Array) from TCGA and GEO databases. According to the median expression of CT83, the TCGA samples were divided into high and low expression groups, and differential expression analysis between them was performed. Functional enrichment analysis of differential expression genes (DEGs) was conducted. Univariate Cox regression analysis and LASSO Cox regression analysis were performed to screen the optimal prognostic DEGs. Then we established the prognostic model. A Nomogram model was constructed to predict the overall survival (OS) probability of LUAD patients.
CT83 expression was significantly correlated to the prognosis of LUAD patients. A total of 59 DEGs were identified, and a predictive model was constructed based on six optimal CT83- related DEGs, including CPS1, RHOV, TNNT1, FAM83A, IGF2BP1, and GRIN2A, which could effectively predict the prognosis of LUAD patients. The nomogram could reliably predict the OS of LUAD patients. Moreover, the six important immune checkpoints (CTLA4, PD1, IDO1, TDO2, LAG3, and TIGIT) were closely correlated with the risk score, which were also differentially expressed between the LUAD samples with high and low risk scores, suggesting that the poor prognosis of LUAD patients with high risk score might be due to the immunosuppressive microenvironments.
A prognostic model based on six optimal CT83 related genes could effectively predict the prognosis of LUAD patients.
本研究旨在探讨 CT83 及其相关基因在肺腺癌（LUAD）中的预后价值。
我们从 TCGA 和 GEO 数据库下载了 513 例 LUAD 患者（RNA 测序数据）和 246 例 NSCLC 患者（Affymetrix Human Genome U133 Plus 2.0 Array）的 mRNA 谱。根据 CT83 的中位数表达，将 TCGA 样本分为高表达和低表达组，并对它们进行差异表达分析。对差异表达基因（DEGs）进行功能富集分析。进行单变量 Cox 回归分析和 LASSO Cox 回归分析，筛选最佳预后 DEGs。然后建立预后模型。构建诺莫图模型预测 LUAD 患者的总生存期（OS）概率。
CT83 的表达与 LUAD 患者的预后显著相关。共鉴定出 59 个 DEGs，并基于六个最佳 CT83 相关 DEGs 构建了一个预测模型，包括 CPS1、RHOV、TNNT1、FAM83A、IGF2BP1 和 GRIN2A，该模型可有效预测 LUAD 患者的预后。诺莫图可以可靠地预测 LUAD 患者的 OS。此外，六个重要的免疫检查点（CTLA4、PD1、IDO1、TDO2、LAG3 和 TIGIT）与风险评分密切相关，且在高风险评分和低风险评分的 LUAD 样本之间也存在差异表达，这表明高风险评分 LUAD 患者的不良预后可能是由于免疫抑制的微环境所致。
基于六个最佳 CT83 相关基因的预后模型可有效预测 LUAD 患者的预后。
